Small Molecules
10 February 2017
Ovid Therapeutics Announces First Patient Randomized in the Phase 2 STARS Clinical Trial in Adults with Angelman Syndrome10 February 2017
Neurocrine and BIAL Announce Exclusive North American Licensing Agreement for Opicapone10 February 2017
FDA Approves EMFLAZA™ (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older9 February 2017
Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS9 February 2017
Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)8 February 2017
Vyome Biosciences Announces Top-Line Results from Phase 1 Study of VB-1953 for Patients with Facial Acne Vulgaris6 February 2017
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency2 February 2017
AMAG Pharmaceuticals Announces Positive Topline Results from Definitive Pharmacokinetic Study for Makena Subcutaneous Administration2 February 2017
Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA5851 February 2017
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue1 February 2017
SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication31 January 2017
Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome31 January 2017
Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery31 January 2017
Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC30 January 2017
Fostamatinib Study Results Continue to Trend Positive30 January 2017
BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines AgencyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports